Brevan Howard Capital Management’s Integra LifeSciences IART Stock Holding History

Brevan Howard Capital Management’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-50,317	Closed	-$474K	–	2294
2026 Q1	$474K	Buy	50,317 +39,095	+348%	+$429K	﹤0.01%	1330
2025 Q4	$139K	Sell	11,222 -32,166	-74%	-$428K	﹤0.01%	1645
2025 Q3	$622K	Buy	+43,388	New	+$594K	﹤0.01%	1171
2025 Q1	–	Sell	-10,279	Closed	-$233K	–	1295
2024 Q4	$233K	Sell	10,279 -3,953	-28%	-$86.3K	﹤0.01%	861
2024 Q3	$259K	Buy	+14,232	New	+$330K	﹤0.01%	913
2024 Q2	–	Sell	-6,287	Closed	-$223K	–	1199
2024 Q1	$223K	Buy	+6,287	New	+$251K	﹤0.01%	762

Other funds holding IART

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCMI

Paradigm Capital Management Inc Albany, New York $3.67B AUM 121.12% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Brevan Howard Capital Management's IART Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Integra LifeSciences (IART) in Q2 2026, closing a stake of 50,317 shares — an estimated $474K sold.

Brevan Howard Capital Management first reported a position in IART in Q1 2024 and held it in 6 quarters. The position peaked at $622K in Q3 2025. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

Brevan Howard Capital Management reported no remaining Integra LifeSciences position as of Q2 2026 after selling out during the quarter.
Brevan Howard Capital Management sold 50,317 Integra LifeSciences shares in Q2 2026, an estimated $474K.
Brevan Howard Capital Management first reported a position in Integra LifeSciences in Q1 2024 and held it in 6 quarters.
Brevan Howard Capital Management's Integra LifeSciences position peaked at $622K in Q3 2025.
212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.